Hệ số tương quan giữa các thông số loại bỏ của Phenytoin và Carbamazepine ở bệnh nhân động kinh nhận cả hai loại thuốc đồng thời: Một nghiên cứu sơ bộ

Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11(6):349–51. Czuczwar SJ, Borowicz KK. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res. 2002;52(1):15–23. Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41(11):1364–74. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9(7):464–8. Brodie MJ, Sills GJ. Combining antiepileptic drugs—rational polytherapy? Seizure. 2011;20(5):369–75. Deckers CLP, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41:1364–71. Mattson RH. Combination therapy with antiepileptic drugs: potential advantages and problems. In: Majkowski J, Bourgeois BFD, Patsalos PN, Mattson RH, editors. Antiepileptic drugs combination therapy and interactions. New York: Cambridge University Press; 2005. p. 16–25. Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG. The efficacy of carbamazepine combination in epilepsy. Clin Pharmacol Ther. 1975;18:733–41. Hakkarainen H. Carbamazepine vs. diphenylhydantoin vs. their combination in adult epilepsy. Neurology. 1980;30:354. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure. 2000;9:464–8. Löscher W. Animal models of intractable epilepsy. Prog Neurobiol. 1997;53(2):239–58. Bauer L. Applied clinical pharmacokinetics. 3rd ed. New York: McGraw-Hill Education; 2014. Winter ME. Phenytoin and fosphenytoin. In: Murphy JE, editor. Clinical pharmacokinetics. Bethesda: American Sociey of Health-System Pharmacists; 2012. p. 273–87. Kutt H, Harden CL. Phenytoin and congeners. In: Eadie MJ, Vajda F, editors. Antiepileptic drugs pharmacology and therapeutics. Berlin: Springer; 1999. p. 229–65. Jolley M, Stroupe S, Schwenzer K, et al. Fluorescence polarization immunoassay. III. An automated system for therapeutic drug determination. Clin Chem. 1981;27(9):1575–9. Lu-Steffes M, Pittluck GW, Jolley ME, et al. Fluorescence polarization immunoassay IV. Determination of phenytoin and phenobarbital in human serum and plasma. Clin Chem. 1982;28(11):2278–82. Winter ME. Basic clinical pharmacokinetics. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol. 1996;51(1):79–85. Faucette SR, Zhang T-C, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320(1):72–80. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002;30(7):795–804. Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K. Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos. 2004;32(4):468–72. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004;279(28):29295–301. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004;32(3):348–58. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347–56. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. Clin Pharmacokinet. 1996;31(3):198–214. Parrish RH, Pazdur DE, O’donnell PJ. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature. Pharmacother J Hum Pharmacol Drug Therapy. 2006;26(11):1650–3. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2005;61(3):246–55. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interaction with phenytoin (part I). Clin Pharmacokinet. 1990;18:131–50. Lai ML, Lin T-S, Huang JD. Effect of single-and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. J Clin Pharmacol. 1992;43:201–3. Gratz ES, Theodore WH, Newmark ME, Kupferberg HJ, Porter RJ, Qu Z. Effect of carbamazepine on phenytoin clearance in patients with complex partial seizure. Neurology. 1982;32:A223. Browne TR, Szabo GK, Evans JE, Greenblat DJ, Mikati MA. Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance. Neurology. 1988;38:1146–50. Lakehal F, Wurden CJ, Kalhorn TF, Levy RH. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res. 2002;52:79–83. Woodbury DM. Phenytoin absorption, distribution, and excretion. In: Woodbury DM, Penry JK, Pippenger CE, editors. Antiepileptic drugs. 2nd ed. New York: Raven Press; 1982. p. 191–207. Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M. Phenytoin-folic acid interaction: a lesson to be learned. Clin Neuropharmacol. 1999;22(5):268–72. Berg MJ, Fincham RW, Ebert BE, Schottelius DD. Phenytoin pharmacokinetics: before and after folic acid administration. Epilepsia. 1992;33(4):712–20. Rivey MP, Schottelius DD, Berg MJ. Phenytoin–folic acid: a review. Ann Pharmacother. 1984;18(4):292–301. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytoin–folic acid interaction. Ann Pharmacother. 1995;29(7–8):726–35.